Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Aspira Women's Health's ovarian cancer test included in AIM Clinical Guidelines » 08:04
07/08/21
07/08
08:04
07/08/21
08:04
AWH

Aspira Women's Health

$5.00 /

-0.12 (-2.34%)

Aspira Women's…

Aspira Women's Health's OVA1 risk assessment test for ovarian cancer in women with pelvic masses is considered medically necessary according to AIM Specialty Health's Clinical Appropriateness Guidelines. AIM Specialty Health is a member of the Anthem Blue Cross Blue Shield family of companies and serves as a specialty benefits management company with many health care organizations. AIM's mission is to promote appropriate, safe, and affordable health care. The OVA1 test is now included in AIM's guidelines for the preoperative evaluation of an adnexal mass when it is indeterminate based on clinical and complete pelvic ultrasound evaluation.

ShowHide Related Items >><<
AWH Aspira Women's Health
$5.00 /

-0.12 (-2.34%)

AWH Aspira Women's Health
$5.00 /

-0.12 (-2.34%)

03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
AWH Aspira Women's Health
$5.00 /

-0.12 (-2.34%)

  • 04
    Feb
Over a month ago
Hot Stocks
Aspira Women's Health releases analytical, initial clinical data for OVASight » 08:04
06/03/21
06/03
08:04
06/03/21
08:04
AWH

Aspira Women's Health

$5.57 /

-0.06 (-1.07%)

Aspira Women's…

Aspira Women's Health released the analytical and initial clinical data for OVASight in an abstract titled "Serum-based Assay for Adnexal Mass Risk of Ovarian Malignancy". Registrants attending the American Society of Clinical Oncology 2021 virtual meeting gained access to the poster on May 19, 2021, and the on-demand presentation will be released to the ASCO virtual meeting registrants at 9:00 a.m. EDT on June 4, 2021 . OVASight is third-generation OVA technology and is a laboratory-developed, blood-based pelvic mass risk assessment test for ovarian cancer in a low prevalence population. It was developed to increase specificity, maintain high sensitivity with early-stage disease, and allow for conservative management of women with a suspected benign mass. A total of 596 samples collected from real-world patients were used to validate the OVASight diagnostic algorithm. Validation data demonstrated 89% Specificity, 91% Sensitivity and a Negative Predictive Value of 99.6% in a low prevalence population. In addition, overall sensitivity as well as sensitivity in early-stage disease were significantly better than CA-125 alone.

ShowHide Related Items >><<
AWH Aspira Women's Health
$5.57 /

-0.06 (-1.07%)

AWH Aspira Women's Health
$5.57 /

-0.06 (-1.07%)

03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
AWH Aspira Women's Health
$5.57 /

-0.06 (-1.07%)

  • 04
    Feb
Conference/Events
Aspira Women's Health management to meet virtually with Truist » 04:55
05/19/21
05/19
04:55
05/19/21
04:55
AWH

Aspira Women's Health

$5.10 /

+0.045 (+0.89%)

Virtual Meeting to be…

Virtual Meeting to be held on May 19 hosted by Truist.

ShowHide Related Items >><<
AWH Aspira Women's Health
$5.10 /

+0.045 (+0.89%)

AWH Aspira Women's Health
$5.10 /

+0.045 (+0.89%)

03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
AWH Aspira Women's Health
$5.10 /

+0.045 (+0.89%)

  • 04
    Feb
Conference/Events
Aspira Women's Health management to meet virtually with Truist » 11:07
05/14/21
05/14
11:07
05/14/21
11:07
AWH

Aspira Women's Health

$5.33 /

+0.5 (+10.35%)

Virtual Meeting to be…

Virtual Meeting to be held on May 19 hosted by Truist.

ShowHide Related Items >><<
AWH Aspira Women's Health
$5.33 /

+0.5 (+10.35%)

AWH Aspira Women's Health
$5.33 /

+0.5 (+10.35%)

03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
AWH Aspira Women's Health
$5.33 /

+0.5 (+10.35%)

  • 04
    Feb
Hot Stocks
Aspira Women's Health to reveal ovarian cancer risk assessment technology » 08:55
05/13/21
05/13
08:55
05/13/21
08:55
AWH

Aspira Women's Health

$4.76 /

-0.18 (-3.64%)

Aspira Women's…

Aspira Women's Health announced that its abstract for "Serum-based Assay for Adnexal Mass Risk of Ovarian Malignancy" will be presented at American Society of Clinical Oncology 2021 meeting which will be held virtually June 4-8, 2021. The accepted abstract presents data demonstrating the analytical validation performance with initial clinical validity data of Aspira's OVASight blood-based biomarker test for ovarian malignancy risk assessment in all women with an adnexal mass. Samples collected from real-world evidence studies with a low prevalence population of malignancy detection were used to validate the algorithm. This third-generation technology, which is a laboratory-developed test, will provide clinicians with a high negative predictive value to provide confidence when managing or monitoring a suspected benign mass, as well as a greater positive predictive value to increase confidence in malignancy risk. The product is expected to be available in Q4 2021.

ShowHide Related Items >><<
AWH Aspira Women's Health
$4.76 /

-0.18 (-3.64%)

AWH Aspira Women's Health
$4.76 /

-0.18 (-3.64%)

03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
AWH Aspira Women's Health
$4.76 /

-0.18 (-3.64%)

  • 04
    Feb
Earnings
Aspira Women's Health reports Q1 EPS (5c), consensus (17c) » 08:21
05/13/21
05/13
08:21
05/13/21
08:21
AWH

Aspira Women's Health

$4.76 /

-0.18 (-3.64%)

Reports Q1 revenue…

Reports Q1 revenue $1.49M, consensus $1.37M. "We are pleased to announce two strategic relationships today. A significant commercial relationship and an innovation collaboration. We expect that these relationships will significantly contribute to our goal of eradicating late stage Ovarian cancer detection," stated Valerie Palmieri, President and CEO.

ShowHide Related Items >><<
AWH Aspira Women's Health
$4.76 /

-0.18 (-3.64%)

AWH Aspira Women's Health
$4.76 /

-0.18 (-3.64%)

03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
  • 04
    Feb
Hot Stocks
Aspira Women's Health initiates clinical study for Ovarian Cancer risk detection » 17:00
05/12/21
05/12
17:00
05/12/21
17:00
AWH

Aspira Women's Health

$4.76 /

-0.18 (-3.64%)

Aspira Women's…

Aspira Women's Health and The Feinstein Institutes for Medical Research, the science arm of Northwell Health, announced the start of a prospective clinical study for Ovarian Cancer risk detection. Northwell Health treats over 2M patients annually and employs over 16,000 credentialed physicians. The study will enroll over 600 prospective women with adnexal masses. The study will also enroll over 2000 women at high risk for Ovarian Cancer, either due to a personal or family history of cancer or are carriers of a germline variant associated with hereditary breast and ovarian cancer syndrome. Ovarian cancer risk will be assessed by both CA125 and Aspira's OVASight proprietary algorithm. The primary objective is to increase total trial enrollment to validate the serial monitoring aspect of the OVASight algorithm in women who present with an adnexal mass. The secondary endpoint is to test additional genomic markers to develop a proteogenomic test for early-stage detection of ovarian cancer. This study will support and collect different biological targets and clinical data metrics to support our innovation pipeline for test development of early diagnosis of ovarian, and other gynecological cancers.

ShowHide Related Items >><<
AWH Aspira Women's Health
$4.76 /

-0.18 (-3.64%)

AWH Aspira Women's Health
$4.76 /

-0.18 (-3.64%)

03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
  • 04
    Feb
Over a quarter ago
Initiation
Aspira Women's Health initiated with a Buy at Truist » 07:07
03/29/21
03/29
07:07
03/29/21
07:07
AWH

Aspira Women's Health

$6.80 /

+0.08 (+1.19%)

Truist analyst Sandy…

Truist analyst Sandy Draper initiated coverage of Aspira Women's Health with a Buy rating and $12 price target. The company's efforts in development an industry-leading diagnostic solutions for diagnosing disease in the pelvic area for women could result in a superior to standard of care option, the analyst tells investors in a research note. Draper is also positive on Aspira's innovation efforts in an area of oncology that has largely remained outside the purview of other diagnostic companies and believes the company may be positioned to address a large market opportunity that could translate into revenue topping $1B within 10 years.

ShowHide Related Items >><<
AWH Aspira Women's Health
$6.80 /

+0.08 (+1.19%)

AWH Aspira Women's Health
$6.80 /

+0.08 (+1.19%)

03/29/21 Truist
Aspira Women's Health initiated with a Buy at Truist
01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
10/29/20 William Blair
Aspira Women's Health initiated with an Outperform at William Blair
  • 04
    Feb
Initiation
Aspira Women's Health initiated with a Buy at Truist » 06:14
03/29/21
03/29
06:14
03/29/21
06:14
AWH

Aspira Women's Health

$6.80 /

+0.08 (+1.19%)

Truist analyst Sandy…

Truist analyst Sandy Draper initiated coverage of Aspira Women's Health with a Buy rating and $12 price target.

ShowHide Related Items >><<
AWH Aspira Women's Health
$6.80 /

+0.08 (+1.19%)

AWH Aspira Women's Health
$6.80 /

+0.08 (+1.19%)

01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
10/29/20 William Blair
Aspira Women's Health initiated with an Outperform at William Blair
  • 04
    Feb
Hot Stocks
Aspira Women's Health: NYS Medicaid considers OVA1 medically necessary » 08:14
03/15/21
03/15
08:14
03/15/21
08:14
AWH

Aspira Women's Health

$7.64 /

-0.05 (-0.65%)

Aspira Women's…

Aspira Women's Health announced its wholly owned subsidiary, Aspira Labs, is now credentialed with New York State's Medicaid program for an estimated additional 6.5 million Medicaid lives. NY State Medicaid will begin to cover Aspira's OVA1 test effective April 1, 2021. The addition of 6.5M NY State Medicaid lives will also increase the total coverage for OVA1 testing to 179M nationwide, the company said in a statement.

ShowHide Related Items >><<
AWH Aspira Women's Health
$7.64 /

-0.05 (-0.65%)

AWH Aspira Women's Health
$7.64 /

-0.05 (-0.65%)

01/28/21 Cantor Fitzgerald
Cantor Fitzgerald starts Aspira Women's Health at Overweight with $10 target
01/28/21 Cantor Fitzgerald
Aspira Women's Health initiated with an Overweight at Cantor Fitzgerald
10/29/20 William Blair
Aspira Women's Health initiated with an Outperform at William Blair
  • 04
    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.